MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, AARD had -$14,590K decrease in cash & cash equivalents over the period. -$54,267K in free cash flow.

Cash Flow Overview

Change in Cash
-$14,590K
Free Cash flow
-$54,267K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from sale and issuance ...
    • Maturities/sales of short-term i...
    • Accrued liabilities
    • Others
Negative Cash Flow Breakdown
    • Purchases of short-term investme...
    • Prepaid expenses and other asset...
    • Financing costs paid in connecti...
    • Others

Cash Flow
2025-12-31
Net loss
-57,591
Credit loss - related party accounts receivable
0
Stock-based compensation expense
3,948
Non-cash lease expense
380
Unrealized loss on short-term investments
-5
Amortization of discount on short-term investments
1,306
Depreciation expense
36
Prepaid expenses and other assets
5,960
Accounts payable
239
Accrued liabilities
6,415
Operating lease liability
-338
Net cash used in operating activities
-54,172
Purchases of short-term investments
129,599
Maturities/sales of short-term investments
80,027
Purchases of property and equipment
95
Net cash used in investing activities
-49,667
Proceeds from sale and issuance of common stock in initial public offering, net of underwriting discounts
91,075
Financing costs paid in connection with initial public offering
2,387
Proceeds from sale and issuance of series c convertible preferred stock
0
Financing costs paid in connection with issuance of series c convertible preferred stock
0
Proceeds from exercises of common stock options
366
Proceeds from issuance of common stock under employee stock purchase plan
195
Costs paid in connection with deferred financing costs
0
Net cash provided by financing activities
89,249
Net (decrease) increase in cash and cash equivalents
-14,590
Cash and cash equivalents at beginning of year
61,641
Cash and cash equivalents at end of year
47,051
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from sale andissuance of common stock...$91,075K Proceeds from exercisesof common stock...$366K Proceeds from issuance ofcommon stock under...$195K Net cash provided byfinancing activities$89,249K Canceled cashflow$2,387K Net (decrease)increase in cash and cash...-$14,590K Canceled cashflow$89,249K Accrued liabilities$6,415K Stock-based compensationexpense$3,948K Non-cash lease expense$380K Accounts payable$239K Depreciation expense$36K Unrealized loss onshort-term investments-$5K Maturities/sales of short-terminvestments$80,027K Financing costs paid inconnection with initial...$2,387K Net cash used inoperating activities-$54,172K Canceled cashflow$11,023K Net cash used ininvesting activities-$49,667K Canceled cashflow$80,027K Net loss-$57,591K Prepaid expenses andother assets$5,960K Amortization of discount onshort-term investments$1,306K Operating lease liability-$338K Purchases of short-terminvestments$129,599K Purchases of property andequipment$95K

Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics, Inc. (AARD)